George 2003.

Study characteristics
Methods	Study design: RCT Country: USA Setting: outpatient smoking research clinic Recruitment: community volunteers
Participants	40 smokers; 63% female; average age 49; average cigarettes per day 23
Interventions	Selegiline. 10 mg/day for 9 weeks (5 mg/day in week 1 and week 9) Placebo
Outcomes	Smoking cessation: 7 day ppa at 6 months. Validated by CO < 10 ppm Adverse events: measured for unspecified period
Funding Source	None specified
Author conflicts of interest	None specified
Notes	"The main side effects of SEL were anorexia, gastrointestinal symptoms, and insomnia. None of the differences in adverse event ratings were significant in the SEL compared with the PLA group, and the drug was well tolerated compared with the placebo group. Reports of anxiety/agitation in both the SEL and PLA groups during the trial were high." Funding: National Institute on Drug Abuse, US Department of Veteran Affairs, National Alliance for Research on Schizophrenia and Depression
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomization method not described
Allocation concealment (selection bias)	Unclear risk	Method not described
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐blind, adequacy of blinding tested in research staff; results suggested blinding was adequate
Incomplete outcome data (attrition bias) All outcomes	High risk	29/40 not assessed at 6 months. Greater loss to follow‐up in placebo, exact data not reported